Active Substance

Substance,active substance,product,treatment,opinion,competent Authorities,body,forms,time,biocidal products,active ingredients,ingredients,human health,diagnosis,principles,biocidal active,authority,regulatory authorities,substance use disorders,drug substance,biological products,Commission,Commission Regulation,diseases,prevention of disease,assessments,review,inactive ingredients,active substance/product-type combination,dosage form,licenses,chemical,non-approval decision.

Application for approval,potential candidate,”220-120-9,Competent authority evaluation”,”222-720-6,Competent authority evaluation”,”225-208-0,Competent authority evaluation”,”233-539-7,Competent authority evaluation”,”-,222-720-6,Competent authority evaluation”,”201-501-9,244-445-0,Competent authority evaluation”,”214-619-0,Competent authority evaluation”,”219-768-5,Competent authority evaluation”,”233-539-7,225-208-0,Competent authority evaluation”,”238-588-8,Competent authority evaluation”,”244-445-0,Competent authority evaluation”,”401-400-1,Competent authority evaluation”,Competent Authority Meeting.

Competent authority report,active substance approval,active substance lists,active substance approval application,active substance generation combinations,active substance glyphosate,complete substance dossier,comprehensive substance,drug products,generic drug product,product candidates,Pesticide products,product performance,already-approved product,biologic product,”220-120-9,Commission decision”,European Commission,”233-539-7,Commission decision”,”262-104-4,Commission decision”.

Commission Implementing Regulation,infantile-onset Pompe disease,late-onset Pompe disease,disease community,disease in patients,disease mechanism,assessment period,diagnostic assessment,assessment phase,assessment report,comparative assessment,Review Programme Regulation,priority review pathway,joint review process,alignment in submission reviews,treatment of people,community treatment programs,comorbidity in treatment,Inert ingredients,positive opinion,”-222-8,Opinion development”,”229-222-8,Opinion development”,substance/product-type combinations,active substance/product-type centric,approved substance/product-type combinations,Health Canada,public health,animal health,body of evidence constituting,body of humans,nanomaterial forms,alternatives over time,application in time,accurate diagnosis,comorbid diagnosis,Biologic License Application,biologics license application,chemical entity,Chemical Types,active principle,basic principle.